Get started
Author

Johannes Sam

Observed names: J Sam, J. Sam, Sam, Johannes
Observed institution: F. Hoffmann-La Roche AG
ORCID: 0000-0002-7455-0609
Observed ORCID: 0000-0002-7455-0609
OpenAlex ID: A5084056228
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2016 · Marina Bacac, Tanja Fauti, et al. · Clinical Cancer Research · 346
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells
2022 · Laura Codarri Deak, Valeria Nicolini, et al. · Nature · 282
PDF
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
2019 · Christina Claus, Claudia Ferrara, et al. · Science Translational Medicine · 272
PDF
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
2018 · Marina Bacac, Sara Colombetti, et al. · Clinical Cancer Research · 250
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity
2020 · Isabelle Solomon, Maria Amann, et al. · Nature Cancer · 206
Innovations, challenges, and minimal information for standardization of humanized mice
2020 · Renata Stripecke, Christian Münz, et al. · EMBO Molecular Medicine · 137
PDF
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
2021 · Inja Waldhauer, Valeria Gonzalez-Nicolini, et al. · mAbs · 120
PDF
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
2020 · Martina Geiger, Kay-Gunnar Stubenrauch, et al. · Nature Communications · 91
PDF
Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies
2021 · S. Jordan Kerns, Chaitra Belgur, et al. · eLife · 82
p95HER2–T cell bispecific antibody for breast cancer treatment
2018 · Irene Rius Ruiz, Rocio Vicario, et al. · Science Translational Medicine · 81
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
2016 · Steffi Lehmann, Ramanil Perera, et al. · Clinical Cancer Research · 71
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody
2021 · Christian Augsberger, Gerulf Hänel, et al. · Blood · 70
Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
2023 · Gabrielle Leclercq-Cohen, Nathalie Steinhoff, et al. · Clinical Cancer Research · 65
PDF
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
2020 · Johannes Sam, Sara Colombetti, et al. · Frontiers in Oncology · 53
PDF
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment
2020 · Christoph M. Griessinger, Tove Olafsen, et al. · Cancer Research · 53
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
2021 · Gabrielle Leclercq, Hélène Haegel, et al. · Journal for ImmunoTherapy of Cancer · 45
PDF
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy
2024 · Johannes Sam, Thomas Hofer, et al. · Blood · 42
PDF
Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model
2021 · Floriana Cremasco, Elena Menietti, et al. · PLoS ONE · 39
PDF
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
2022 · Gabrielle Leclercq, Hélène Haegel, et al. · Journal for ImmunoTherapy of Cancer · 36
PDF
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma
2022 · Raffaella Iurlaro, Inja Waldhauer, et al. · Molecular Cancer Therapeutics · 35
PDF
Corrigendum: Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
2021 · Johannes Sam, Sara Colombetti, et al. · Frontiers in Oncology · 30
PDF
CD20 Tcb (RG6026), a Novel "2:1" T Cell Bispecific Antibody for the Treatment of B Cell Malignancies
2016 · Marina Bacac, Pablo Umaña, et al. · Blood · 24
Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2
2016 · Werner Scheuer, Markus Thomas, et al. · mAbs · 23
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma
2025 · Johannes Sam, Gabrielle Leclercq-Cohen, et al. · Blood · 13
PDF
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid
2021 · Miro Julian Eigenmann, Tine Veronica Karlsen, et al. · Pharmaceutics · 10
PDF
Works count: 271
Citation count: 2,582
H-index: 23
I10-index: 25
Year
Topic
Type